MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
SCWorx Corp. Balance Sheet 2011-2025 | WORX
Annual Balance Sheet SCWorx Corp.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | - | -376 K | -488 K | 1.4 M | -48.2 K | -4.68 M | 353 K | - | - | - | - |
Total Non Current Liabilities |
19.7 K | 90.4 K | 148 K | 434 K | - | - | - | 23.9 K | - | - | - | - | - | - |
Total Current Liabilities |
1.84 M | 2.33 M | 2.32 M | 2.28 M | 4.6 M | 3.07 M | 8.57 M | 1.6 M | 284 K | - | - | - | - | - |
Total Liabilities |
1.86 M | 2.42 M | 2.47 M | 2.72 M | 4.89 M | 3.07 M | 8.57 M | 1.62 M | 284 K | 406 K | - | - | - | - |
Deferred Revenue |
354 K | 379 K | 580 K | 473 K | 2.03 M | 1.06 M | - | 56.7 K | - | - | - | - | - | - |
Retained Earnings |
-31 M | -29.8 M | -25.9 M | -24 M | - | -12.8 M | -31.3 M | -16.5 M | -4.55 M | -386 K | - | - | - | - |
Total Assets |
6.35 M | 6.28 M | 9.25 M | 9.12 M | 10.6 M | 9.99 M | 5.66 M | 9.76 M | 14 M | 25 K | - | - | - | - |
Cash and Cash Equivalents |
107 K | 91.4 K | 249 K | 71.1 K | 376 K | 488 K | 76.5 K | 42.8 K | 4.68 M | - | - | - | - | - |
Book Value |
4.49 M | 3.85 M | 6.78 M | 6.41 M | 5.73 M | 6.93 M | -2.91 M | 8.13 M | 13.7 M | -381 K | - | - | - | - |
Total Shareholders Equity |
4.49 M | 3.85 M | 6.78 M | 6.41 M | 5.73 M | 6.93 M | -232 K | 8.13 M | 13.7 M | -381 K | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet SCWorx Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
2.11 K | 7.95 K | 7.04 K | 19.7 K | 7.11 K | - | - | 90.4 K | 99.9 K | 114 K | 129 K | 148 K | 154 K | 294 K | 294 K | 434 K | 434 K | 434 K | 434 K | 294 K | 294 K | 294 K | 294 K | - | - | - | - | 1.59 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
1.18 M | 1.2 M | 1.56 M | 1.86 M | 2.04 M | 2.91 M | 2.64 M | 2.42 M | 2.66 M | 2.45 M | 2.75 M | 2.47 M | 2.48 M | 2.92 M | 3.14 M | 2.72 M | 3.75 M | 4.03 M | 4.87 M | 4.89 M | 4.89 M | 4.89 M | 4.89 M | 3.07 M | 3.07 M | 3.07 M | 2.3 M | 3.26 M | 3.26 M | 3.26 M | 3.26 M | 1.62 M | 1.62 M | 1.62 M | 1.62 M | 284 K | - | 284 K | 284 K | 406 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
399 K | 219 K | 333 K | 354 K | 159 K | 388 K | 410 K | 379 K | 392 K | 586 K | 735 K | 580 K | 298 K | 589 K | 764 K | 473 K | 596 K | 921 K | 1.96 M | 2.03 M | 2.03 M | 2.03 M | 2.03 M | 1.06 M | 1.06 M | 1.06 M | 1.06 M | 817 K | 817 K | 817 K | 817 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-34.7 M | -33.4 M | -31.5 M | -31 M | -30.8 M | -30.4 M | -30 M | -29.8 M | -27.3 M | -26.4 M | -26.3 M | -25.9 M | -25.6 M | -25.2 M | -24.6 M | -24 M | -23.2 M | -22.2 M | -20.9 M | -20.2 M | -20.2 M | -20.2 M | -20.2 M | -12.8 M | -12.8 M | -12.8 M | -12.8 M | -1.48 M | -1.48 M | -1.48 M | -1.48 M | -16.5 M | -16.5 M | -16.5 M | -16.5 M | -4.55 M | -4.55 M | -4.55 M | -4.55 M | -386 K | -386 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
7.18 M | 6.65 M | 7.16 M | 6.35 M | 6.52 M | 6.51 M | 6.34 M | 6.28 M | 8.82 M | 9.05 M | 9.28 M | 9.25 M | 9.28 M | 9.06 M | 9.35 M | 9.12 M | 9.56 M | 9.39 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 9.99 M | 9.99 M | 9.99 M | 9.99 M | 3.03 M | 3.03 M | 3.03 M | 3.03 M | 9.76 M | 9.76 M | 9.76 M | 9.76 M | 14 M | 14 M | 14 M | 14 M | 25 K | 25 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
684 K | 340 K | 1.07 M | 107 K | 87.7 K | 17.3 K | 39.6 K | 91.4 K | 72.4 K | 133 K | 250 K | 249 K | 362 K | 23.5 K | 8.29 K | 71.1 K | 402 K | 32.1 K | 89.1 K | 376 K | 376 K | 376 K | 376 K | 488 K | 488 K | 488 K | 488 K | 76.5 K | 76.5 K | 76.5 K | 76.5 K | 15.2 K | 42.8 K | 257 K | 348 K | 4.57 M | 4.68 M | 4.68 M | 4.68 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
6 M | 5.45 M | 5.59 M | 4.49 M | 4.48 M | 3.61 M | 3.7 M | 3.85 M | 6.16 M | 6.59 M | 6.52 M | 6.78 M | 6.8 M | 6.15 M | 6.21 M | 6.41 M | 5.81 M | 5.35 M | 5.74 M | 5.73 M | 5.73 M | 5.73 M | 5.73 M | 6.93 M | 6.93 M | 6.93 M | 7.69 M | -232 K | -232 K | -232 K | -232 K | 8.13 M | 8.13 M | 8.13 M | 8.13 M | 13.7 M | 14 M | 13.7 M | 13.7 M | -381 K | 25 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
6 M | 5.45 M | 5.59 M | 4.49 M | 4.48 M | 3.61 M | 3.7 M | 3.85 M | 6.16 M | 6.59 M | 6.52 M | 6.78 M | 6.8 M | 6.15 M | 6.21 M | 6.41 M | 5.81 M | 5.35 M | 5.74 M | 5.73 M | 5.73 M | 5.73 M | 5.73 M | 6.93 M | 6.93 M | 6.93 M | 6.93 M | -232 K | -232 K | -232 K | -232 K | -1.1 M | 8.13 M | 8.13 M | 8.13 M | 13.7 M | 13.7 M | 13.7 M | 13.7 M | -381 K | -381 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of SCWorx Corp., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Health information services
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Covetrus
CVET
|
- | - | $ 2.94 B |  USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Evolent Health
EVH
|
$ 4.08 | -1.21 % | $ 382 M | USA |
 |
Health Catalyst
HCAT
|
$ 2.43 | 0.41 % | $ 146 M | USA |
 |
HealthStream
HSTM
|
$ 23.27 | -1.44 % | $ 707 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
HealthEquity
HQY
|
$ 92.92 | -0.6 % | $ 7.95 B | USA |
 |
Progyny
PGNY
|
$ 25.88 | 0.31 % | $ 2.22 B | USA |
 |
American Well Corporation
AMWL
|
$ 4.62 | 1.43 % | $ 69.3 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 12.33 | -1.2 % | $ 211 M | USA |
 |
Schrödinger
SDGR
|
$ 17.88 | -2.38 % | $ 1.3 B | USA |
 |
GoodRx Holdings
GDRX
|
$ 2.71 | -1.64 % | $ 1.05 B | USA |
 |
So-Young International
SY
|
$ 2.5 | -5.13 % | $ 198 M |  China |
 |
Omnicell
OMCL
|
$ 46.18 | -0.48 % | $ 2.13 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
Phreesia
PHR
|
$ 16.93 | -0.41 % | $ 924 M | USA |
 |
Premier
PINC
|
$ 28.26 | - | $ 2.33 B | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
10x Genomics
TXG
|
$ 16.11 | -2.3 % | $ 1.89 B | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
Zhongchao
ZCMD
|
$ 0.46 | -9.63 % | $ 2.39 M | China |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
Teladoc Health
TDOC
|
$ 6.97 | -2.18 % | $ 1.19 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Veeva Systems
VEEV
|
$ 223.59 | -0.47 % | $ 35.9 B | USA |